General Information of Drug (ID: DMA9VDN)

Drug Name
L-760790 Drug Info
Synonyms L-760790; CHEMBL420965; SCHEMBL4358113; JCFDYNJSFCXYRT-FQEVSTJZSA-N; BDBM50060425; Benzyl-{(S)-1-[2-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-ethyl]-pyrrolidin-3-ylmethyl}-amine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10386282
TTD Drug ID
DMA9VDN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
Eletriptan DMW649X Migraine 8A80 Approved [3]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [3]
Frovatriptan DM7RE8P Migraine 8A80 Approved [3]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [4]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [5]
Almogran DM7I64Z Migraine 8A80 Approved [6]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [7]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [8]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Inhibitor [1]

References

1 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1999 Feb 25;42(4):691-705.
2 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
5 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
6 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
7 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Company report (NeurAxon)